HUP0402594A2 - Rapamycint és származékait tartalmazó hatóanyag-leadó rendszerek érbetegségek megelőzésére és kezelésére - Google Patents

Rapamycint és származékait tartalmazó hatóanyag-leadó rendszerek érbetegségek megelőzésére és kezelésére

Info

Publication number
HUP0402594A2
HUP0402594A2 HU0402594A HUP0402594A HUP0402594A2 HU P0402594 A2 HUP0402594 A2 HU P0402594A2 HU 0402594 A HU0402594 A HU 0402594A HU P0402594 A HUP0402594 A HU P0402594A HU P0402594 A2 HUP0402594 A2 HU P0402594A2
Authority
HU
Hungary
Prior art keywords
prevention
treatment
drug delivery
delivery systems
rapamycin
Prior art date
Application number
HU0402594A
Other languages
English (en)
Inventor
Margaret Forney Prescott
Walter Schuler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0402594A2 publication Critical patent/HUP0402594A2/hu
Publication of HUP0402594A3 publication Critical patent/HUP0402594A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)

Abstract

A találmány proliferatív betegségek, különösen érrendszeri betegségekmegelőzésére és kezelésére szolgáló gyógyszerhatóanyag-leadórendszerekre vonatkozik A tatálmány rapamycint vagy mTOR- gátló hatásúrapamycinszármazékot tartalmaz, adott esetben egy vagy több aktívkoágenssel együtt.
HU0402594A 2002-01-10 2003-01-09 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof HUP0402594A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34726402P 2002-01-10 2002-01-10
PCT/EP2003/000153 WO2003057218A1 (en) 2002-01-10 2003-01-09 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof

Publications (2)

Publication Number Publication Date
HUP0402594A2 true HUP0402594A2 (hu) 2005-10-28
HUP0402594A3 HUP0402594A3 (en) 2006-01-30

Family

ID=23363001

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402594A HUP0402594A3 (en) 2002-01-10 2003-01-09 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof

Country Status (19)

Country Link
US (5) US20050020614A1 (hu)
EP (1) EP1465624A1 (hu)
JP (1) JP2005514411A (hu)
KR (1) KR20040076278A (hu)
CN (1) CN1615137A (hu)
AU (1) AU2003205586A1 (hu)
BR (1) BR0306858A (hu)
CA (1) CA2472198A1 (hu)
CO (1) CO5601015A2 (hu)
EC (1) ECSP085181A (hu)
HU (1) HUP0402594A3 (hu)
IL (1) IL162719A0 (hu)
MX (1) MXPA04006731A (hu)
NO (1) NO20043309L (hu)
PL (1) PL369671A1 (hu)
RU (3) RU2004124387A (hu)
TW (2) TW200306826A (hu)
WO (1) WO2003057218A1 (hu)
ZA (1) ZA200405118B (hu)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7713297B2 (en) * 1998-04-11 2010-05-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US20060240070A1 (en) * 1998-09-24 2006-10-26 Cromack Keith R Delivery of highly lipophilic agents via medical devices
US7455853B2 (en) 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
EP1582180B1 (en) 2000-10-16 2008-02-27 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
US20050125054A1 (en) * 2000-12-22 2005-06-09 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US20030033007A1 (en) * 2000-12-22 2003-02-13 Avantec Vascular Corporation Methods and devices for delivery of therapeutic capable agents with variable release profile
US20020082679A1 (en) * 2000-12-22 2002-06-27 Avantec Vascular Corporation Delivery or therapeutic capable agents
US7077859B2 (en) * 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20050203612A1 (en) * 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
CN100469394C (zh) * 2001-02-16 2009-03-18 艾伯特实验室血管有限公司 具有fk506的植入体
US8182527B2 (en) 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US10441747B2 (en) * 2002-01-22 2019-10-15 Mercator Medsystems, Inc. Methods and systems for inhibiting vascular inflammation
IL162734A0 (en) 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
EP1485042A1 (en) * 2002-03-18 2004-12-15 Medtronic AVE Inc. Medical devices for delivering anti-proliferative compositions to anatomical sites at risk of restenosis
US20040133270A1 (en) * 2002-07-08 2004-07-08 Axel Grandt Drug eluting stent and methods of manufacture
US20050214343A1 (en) * 2002-07-18 2005-09-29 Patrice Tremble Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
PL375698A1 (en) * 2002-09-06 2005-12-12 Abbott Laboratories Medical device having hydration inhibitor
US9770349B2 (en) * 2002-11-13 2017-09-26 University Of Virginia Patent Foundation Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation
CA2516175A1 (en) * 2003-02-18 2004-09-02 Medtronic, Inc. Occlusion resistant hydrocephalic shunt
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
US8088404B2 (en) * 2003-03-20 2012-01-03 Medtronic Vasular, Inc. Biocompatible controlled release coatings for medical devices and related methods
US20040254629A1 (en) * 2003-04-25 2004-12-16 Brian Fernandes Methods and apparatus for treatment of aneurysmal tissue
US20050033417A1 (en) * 2003-07-31 2005-02-10 John Borges Coating for controlled release of a therapeutic agent
EP1656163B1 (en) * 2003-08-13 2014-08-06 Poly-Med, Inc. Biocompatible controlled release coatings for medical devices and related methods
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US7659244B2 (en) 2003-11-03 2010-02-09 Quest Pharmatech, Inc. Rapamycin peptides conjugates: synthesis and uses thereof
WO2005049021A1 (en) * 2003-11-03 2005-06-02 Oy Helsinki Transplantation R & D Ltd Materials and methods for inhibiting neointimal hyperplasia
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
US7303758B2 (en) * 2004-01-20 2007-12-04 Cordis Corporation Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
WO2005075003A1 (en) * 2004-01-21 2005-08-18 Medtronic Vascular Inc. Implantable medical devices for treating or preventing restenosis
CA2552759A1 (en) * 2004-01-22 2005-08-04 Novartis Ag Combination of organic compounds
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US20070027523A1 (en) * 2004-03-19 2007-02-01 Toner John L Method of treating vascular disease at a bifurcated vessel using coated balloon
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US20050220836A1 (en) * 2004-03-31 2005-10-06 Robert Falotico Drug delivery device
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
US8163269B2 (en) * 2004-04-05 2012-04-24 Carpenter Kenneth W Bioactive stents for type II diabetics and methods for use thereof
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
MXPA06013294A (es) * 2004-05-17 2007-02-02 Novartis Ag Combinacion de compuestos organicos.
US20050287184A1 (en) * 2004-06-29 2005-12-29 Hossainy Syed F A Drug-delivery stent formulations for restenosis and vulnerable plaque
WO2006020755A2 (en) * 2004-08-10 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
US20060051338A1 (en) * 2004-08-20 2006-03-09 New York University Inhibition of mitogen-activated protein kinases in cardiovascular disease
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
US20090041778A1 (en) * 2004-11-22 2009-02-12 Sukhatme Vikas P Methods And Compositions For The Treatment Of Graft Failure
US20060127443A1 (en) * 2004-12-09 2006-06-15 Helmus Michael N Medical devices having vapor deposited nanoporous coatings for controlled therapeutic agent delivery
US20060129215A1 (en) * 2004-12-09 2006-06-15 Helmus Michael N Medical devices having nanostructured regions for controlled tissue biocompatibility and drug delivery
US20060204546A1 (en) * 2005-03-14 2006-09-14 Conor Medsystems, Inc. Methods and systems for delivering immunosuppressant and anti-inflammatory agents from a stent
JP5271697B2 (ja) * 2005-03-23 2013-08-21 アボット ラボラトリーズ 医療装置を介する高親油性薬剤の送達
US7252834B2 (en) 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
BRPI0611021A2 (pt) * 2005-05-31 2010-08-10 Novartis Ag combinação de inibidores de hmg-coa redutase e inibidores de mtor
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
US20070038176A1 (en) * 2005-07-05 2007-02-15 Jan Weber Medical devices with machined layers for controlled communications with underlying regions
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
WO2007011707A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
WO2007053578A2 (en) * 2005-10-31 2007-05-10 Amulet Pharmaceuticals, Inc. Multi-phasic nitric oxide and drug co-eluting stent coatings
US20070116736A1 (en) * 2005-11-23 2007-05-24 Argentieri Dennis C Local vascular delivery of PI3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury
US20070196327A1 (en) * 2005-12-06 2007-08-23 Amulet Pharmaceuticals, Inc. Nitric oxide releasing polymers
US20070203171A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Combination of rapamycin and its tetrazole isomers and epimers, methods of making and using the same
US20070224235A1 (en) * 2006-03-24 2007-09-27 Barron Tenney Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) * 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
PL2019657T3 (pl) 2006-04-26 2015-10-30 Micell Technologies Inc Powłoki zawierające wiele leków
US20080051335A1 (en) * 2006-05-02 2008-02-28 Kleiner Lothar W Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers
US7868531B2 (en) * 2006-05-05 2011-01-11 Brother International Corporation Carbon nanotube arrays for field electron emission
US20070264303A1 (en) * 2006-05-12 2007-11-15 Liliana Atanasoska Coating for medical devices comprising an inorganic or ceramic oxide and a therapeutic agent
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US20080004695A1 (en) * 2006-06-28 2008-01-03 Abbott Cardiovascular Systems Inc. Everolimus/pimecrolimus-eluting implantable medical devices
JP2009542359A (ja) * 2006-06-29 2009-12-03 ボストン サイエンティフィック リミテッド 選択的被覆部を備えた医療装置
US20080039362A1 (en) * 2006-08-09 2008-02-14 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US9173733B1 (en) * 2006-08-21 2015-11-03 Abbott Cardiovascular Systems Inc. Tracheobronchial implantable medical device and methods of use
MX2009001857A (es) * 2006-08-22 2009-03-02 Novartis Ag Tratamiento de trastornos fibrosantes.
BRPI0715656A2 (pt) * 2006-08-28 2013-07-02 Wyeth Corp sistemas de derivaÇço implantÁvel para drenar fluido de uma cavidade corporal, e de derivaÇço de fluido cerebrospinal, e, uso de um agente terapÊutico
EP2068757B1 (en) 2006-09-14 2011-05-11 Boston Scientific Limited Medical devices with drug-eluting coating
EP2084310A1 (en) * 2006-10-05 2009-08-05 Boston Scientific Limited Polymer-free coatings for medical devices formed by plasma electrolytic deposition
US9539593B2 (en) * 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
CA2669415A1 (en) * 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
US7713541B1 (en) 2006-11-21 2010-05-11 Abbott Cardiovascular Systems Inc. Zwitterionic terpolymers, method of making and use on medical devices
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
EP2125895B1 (en) 2007-02-02 2015-04-08 Vegenics Pty Ltd Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
KR101158981B1 (ko) * 2007-04-17 2012-06-21 미셀 테크놀로지즈, 인코포레이티드 생체분해성 층을 갖는 스텐트
US7976915B2 (en) * 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
JP2010527746A (ja) * 2007-05-25 2010-08-19 ミセル テクノロジーズ、インコーポレイテッド メディカルデバイスコーティング用ポリマーフィルム
US7942926B2 (en) * 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8002823B2 (en) * 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
EP2187988B1 (en) 2007-07-19 2013-08-21 Boston Scientific Limited Endoprosthesis having a non-fouling surface
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8815273B2 (en) * 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
CA2693338A1 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
WO2009018340A2 (en) * 2007-07-31 2009-02-05 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
JP2010535541A (ja) * 2007-08-03 2010-11-25 ボストン サイエンティフィック リミテッド 広い表面積を有する医療器具用のコーティング
US20090104240A1 (en) * 2007-10-19 2009-04-23 Abbott Cardiovascular Systems Inc. Dual Drug Formulations For Implantable Medical Devices For Treatment of Vascular Diseases
WO2009051780A1 (en) * 2007-10-19 2009-04-23 Micell Technologies, Inc. Drug coated stents
US20090118809A1 (en) * 2007-11-02 2009-05-07 Torsten Scheuermann Endoprosthesis with porous reservoir and non-polymer diffusion layer
US7938855B2 (en) * 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8029554B2 (en) * 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US20090118818A1 (en) * 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Endoprosthesis with coating
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20090155337A1 (en) * 2007-11-12 2009-06-18 Endologix, Inc. Method and agent for in-situ stabilization of vascular tissue
US20090214654A1 (en) * 2008-02-21 2009-08-27 Isenburg Jason C Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
CN102083397B (zh) * 2008-04-17 2013-12-25 米歇尔技术公司 具有生物可吸收层的支架
WO2009131911A2 (en) 2008-04-22 2009-10-29 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
WO2009132176A2 (en) 2008-04-24 2009-10-29 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
EP2303350A2 (en) 2008-06-18 2011-04-06 Boston Scientific Scimed, Inc. Endoprosthesis coating
WO2009158031A2 (en) * 2008-06-27 2009-12-30 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
US9486431B2 (en) * 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
KR20110074758A (ko) * 2008-10-03 2011-07-01 엘릭서 메디컬 코포레이션 마크로사이클릭 락톤 화합물 및 이를 사용하는 방법
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
US8231980B2 (en) * 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US8071156B2 (en) * 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US20100256746A1 (en) * 2009-03-23 2010-10-07 Micell Technologies, Inc. Biodegradable polymers
US20100241220A1 (en) * 2009-03-23 2010-09-23 Mcclain James B Peripheral Stents Having Layers
US9981072B2 (en) * 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
US20100274352A1 (en) * 2009-04-24 2010-10-28 Boston Scientific Scrimed, Inc. Endoprosthesis with Selective Drug Coatings
US8287937B2 (en) * 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
US8496911B2 (en) * 2009-07-29 2013-07-30 Vatrix CHF, Inc. Tissue stabilization for heart failure
US20110218517A1 (en) * 2009-10-09 2011-09-08 Ogle Matthew F In vivo chemical stabilization of vulnerable plaque
US8444624B2 (en) 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US8951595B2 (en) * 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
US8480620B2 (en) * 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US20110144577A1 (en) * 2009-12-11 2011-06-16 John Stankus Hydrophilic coatings with tunable composition for drug coated balloon
EP2531140B1 (en) * 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8795762B2 (en) * 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
EP2558026A4 (en) * 2010-04-16 2013-10-23 Micell Technologies Inc STENTS WITH TAXED ELUTION
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
WO2012034079A2 (en) 2010-09-09 2012-03-15 Micell Technologies, Inc. Macrolide dosage forms
WO2012047813A1 (en) * 2010-10-04 2012-04-12 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
WO2012158944A1 (en) 2011-05-18 2012-11-22 Vatrix Medical, Inc. Coated balloons for blood vessel stabilization
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US9220716B2 (en) * 2011-07-26 2015-12-29 Children's Medical Center Corporation Methods and compositions for the treatment of proliferative vascular disorders
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US20140094900A1 (en) * 2012-10-01 2014-04-03 Brigham Young University Compliant biocompatible device and method of manufacture
EP2967803B1 (en) 2013-03-12 2023-12-27 Micell Technologies, Inc. Bioabsorbable biomedical implants
WO2014160358A1 (en) * 2013-03-14 2014-10-02 Thomas Cooper Woods Use of mir-221 and 222 lowering agents to prevent cardiovascular disease in diabetic subjects
US9522130B2 (en) 2013-03-14 2016-12-20 Thomas Cooper Woods Use of miR-221 and 222 lowering agents to prevent cardiovascular disease in diabetic subjects
EP2994758B1 (en) 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
WO2016100782A1 (en) * 2014-12-18 2016-06-23 University Of South Carolina Suppression of neointimal formation following vascular surgery using cdk8 inhibitors
KR20190056401A (ko) 2016-09-22 2019-05-24 머케이터 메드시스템즈, 인크. 템시롤리무스를 사용하는 재협착의 치료
US10576063B2 (en) 2017-05-26 2020-03-03 Mercator Medsystems, Inc. Combination therapy for treatment of restenosis
CN109010931B (zh) * 2017-06-09 2022-03-11 上海微创医疗器械（集团）有限公司 介入医疗器械及阿非迪霉素的应用
WO2019104065A1 (en) * 2017-11-22 2019-05-31 Turrinii Pharmaceutical, Llc Anti-aging methods and compositions
US11654267B2 (en) 2018-03-14 2023-05-23 Mercator Medsystems, Inc. Medical instrument and medical method for localized drug delivery
CA3107349A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
WO2020023418A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
EP3952947A4 (en) 2019-04-11 2024-07-03 Enclear Therapies Inc METHODS FOR IMPROVING CEREBRAL SPINAL FLUID AND DEVICES AND SYSTEMS THEREFOR

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US123505A (en) * 1872-02-06 Improvement in wheel-plows
US27340A (en) * 1860-03-06 Improvement in steam-boilers
US7213A (en) * 1850-03-26 Improvement in seed-planters
US82680A (en) * 1868-10-06 Rufus e
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
NL1006553C2 (nl) * 1997-07-11 1999-01-12 Hoogovens Staal Bv Werkwijze voor het sturen (control) van een smelting reduction process.
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7208010B2 (en) * 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20010029351A1 (en) * 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
EP1150671B1 (en) * 1998-11-20 2007-02-28 The General Hospital Corporation Use of pyrethroid compounds to promote hair growth
US20020007213A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US6641611B2 (en) * 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US6805703B2 (en) * 2001-09-18 2004-10-19 Scimed Life Systems, Inc. Protective membrane for reconfiguring a workpiece
US7025734B1 (en) * 2001-09-28 2006-04-11 Advanced Cardiovascular Systmes, Inc. Guidewire with chemical sensing capabilities
BR0308053A (pt) * 2002-02-28 2004-12-28 Novartis Ag Stents revestidos com n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina

Also Published As

Publication number Publication date
PL369671A1 (en) 2005-05-02
MXPA04006731A (es) 2004-10-04
RU2004124387A (ru) 2005-06-10
TW200730152A (en) 2007-08-16
RU2008107255A (ru) 2009-09-10
IL162719A0 (en) 2005-11-20
JP2005514411A (ja) 2005-05-19
KR20040076278A (ko) 2004-08-31
ZA200405118B (en) 2005-06-21
CN1615137A (zh) 2005-05-11
US20090036352A1 (en) 2009-02-05
RU2008150750A (ru) 2010-06-27
AU2003205586A1 (en) 2003-07-24
CA2472198A1 (en) 2003-07-17
HUP0402594A3 (en) 2006-01-30
US20050020614A1 (en) 2005-01-27
ECSP085181A (es) 2008-09-29
CO5601015A2 (es) 2006-01-31
EP1465624A1 (en) 2004-10-13
NO20043309L (no) 2004-08-09
WO2003057218A1 (en) 2003-07-17
US20060127440A1 (en) 2006-06-15
BR0306858A (pt) 2004-11-03
US20090043379A1 (en) 2009-02-12
US20030170287A1 (en) 2003-09-11
TW200306826A (en) 2003-12-01

Similar Documents

Publication Publication Date Title
HUP0402594A2 (hu) Rapamycint és származékait tartalmazó hatóanyag-leadó rendszerek érbetegségek megelőzésére és kezelésére
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
WO2003080582A3 (de) Fredericamycin-derivate
AU2003220317A1 (en) Methods and drug delivery systems for the treatment of orofacial diseases
WO2006060547A3 (en) Systems and methods for intra-oral drug delivery
TNSN08079A1 (en) Pharmaceutical compositions for the treatment of inner ear disorders
ATE448812T1 (de) Beschichtung von stents mit verzögerter wirkstofffreisetzung
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
DK1663244T3 (da) Pteridin-derivater til behandling af TNF-alpha-beslægtede sygdomme
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
AU2002358082A1 (en) Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
DK1150704T3 (da) Melagatran til behandling af betændelse
WO2007057436A3 (en) Interferon in influenza
WO2004006830A3 (en) Use of ccn protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
UA85187C2 (en) 2-aminobenzoyl derivatives
DE60233647D1 (de) Reduziertes vitamin b2 enthaltende arzneimittel
UA89858C2 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
AU2002228391A1 (en) Medicinal composition for diagnosis, prevention, or therapy of multiple risk factor syndrome
ECSP045181A (es) Sistema de administración de fármacos que comprenden rapamicina y derivados de la misma para la prevención y tratamiento de enfermedades vasculares

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees